Overview

Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.

Eligibility

Inclusion Criteria:

• Volunteer to participate in the trial, with the patient or their legal guardian signing the informed consent form;
• Volunteers are not limited by gender, and the age range is from 18 to 75 years old, inclusive;
• Other imaging examination methods (CT, MRI, etc.) reveal tumor occupying lesions;
• Tumor patients who can obtain the final pathological results.
• Kidney: GFR \> 50 ml/min, ERPF \> 280 ml/min, platelet count (PLT) \> 75,000/μL, white blood cell (WBC) \> 3,000/μL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the normal value.

Exclusion Criteria:

• Individuals with a history of allergy to similar drugs (drugs with similar chemical or biological components to CCK2R), allergic constitution, or current allergic diseases;
• Those who are currently participating in other clinical drug studies, or have previously participated in any clinical drug studies (excluding vitamins and minerals);
• Other uncontrollable clinical issues (such as HIV, hepatitis C virus infection, active hepatitis B, or other severe chronic infections, as well as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases);
• Red blood cells (RBC) count less than 4×10\^12, white blood cells (WBC) count less than 3×10\^9, hemoglobin level less than 110g/L, and platelet count (PLT) less than 75,000×10\^9;
• Obvious abnormalities in liver and kidney function, with GFR less than 50 ml/min;
• Tumor burden greater than 50%, or significant spinal cord compression;
• Expected survival duration less than half a year; chemotherapy within 6 months;
• Having severe acute concomitant diseases or severe treatment-resistant mental disorders;
• Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy test result);
• Patients who are physically unfit for radiological examinations;
• Other situations where the researcher deems it inappropriate for the participant to participate in the trial.